SB268 HFA Summer 3-3 #1

CR 3338

Delegate Summers moved to amend the amendment on page 2, line 17, by inserting the following:

“"Device" means a blood glucose test strip, glucometer, continuous glucose monitor (CGM), lancet, lancing device, or insulin syringe used to cure, diagnose, mitigate, prevent, or treat diabetes or low blood sugar, but does not include insulin pumps.”;

And,

On page 32, line 1, by striking subsection (a) in its entirety and inserting in lieu thereof a new subsection (a) to read as follows:

“(a) A policy, plan, or contract that is issued or renewed on or after January 1, 2023 shall provide coverage for prescription insulin drugs and equipment pursuant to this section.”

And,

On page 32, line 13, on page 32, line 13, by striking new subsection (b) in its entirety and inserting a new subsection (b) to read as follows:

“(c) Cost sharing for a 30-day supply of a covered prescription insulin drug may not exceed $35 in aggregate, including situations where the covered person is prescribed more than one insulin drug, per 30-day supply, regardless of the amount or type of insulin needed to fill such covered person’s prescription. Cost sharing for a 30-day supply of covered device(s) may not exceed $100 in aggregate, including situations where the covered person is prescribed more than one device, per 30-day supply. Each cost-share maximum is covered regardless of the person's deductible, copayment, coinsurance or any other cost-sharing requirement.”

Adopted

Rejected